PULMOTECT
Pulmotect is a biopharma company that develops products that boost the innate immune system to protect against a wide range of lung infections. Its technology stimulates the body’s natural defenses to provide safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). It was founded in 2007 and is headquartered in Houston, Texas.
PULMOTECT
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2007-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.pulmotect.com
Total Employee:
1+
Status:
Active
Contact:
7135799226
Email Addresses:
[email protected]
Total Funding:
28.35 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Current Advisors List
Current Employees Featured
Founder
Investors List
Jefferson River Capital
Jefferson River Capital investment in Series B - Pulmotect
Fannin Innovation Studio
Fannin Innovation Studio investment in Series B - Pulmotect
Aquinas
Aquinas investment in Series B - Pulmotect
Houston Angel Network
Houston Angel Network investment in Series A - Pulmotect
Fannin Innovation Studio
Fannin Innovation Studio investment in Series A - Pulmotect
National Institutes of Health
National Institutes of Health investment in Grant - Pulmotect
National Heart, Lung and Blood Institute
National Heart, Lung and Blood Institute investment in Grant - Pulmotect
Cancer Prevention and Research Institute of Texas
Cancer Prevention and Research Institute of Texas investment in Grant - Pulmotect
Official Site Inspections
http://www.pulmotect.com Semrush global rank: 5.76 M Semrush visits lastest month: 1.45 K
- Host name: wh1.tomohost.com
- IP address: 209.59.160.36
- Location: Lansing United States
- Latitude: 42.7348
- Longitude: -84.6245
- Metro Code: 551
- Timezone: America/Detroit
- Postal: 48917
More informations about "Pulmotect"
Our Company – Pulmotect, Inc.
Pulmotect is pioneering an immunomodulatory and “pathogen agnostic” approach to preventing and treating respiratory complications by harnessing the power of the innate immune system. … See details»
Pulmotect - Crunchbase Company Profile & Funding
Pulmotect is a biopharma company that develops products that boost the innate immune system to protect against a wide range of lung infections. Its … See details»
Pulmotect Company Profile | Management and Employees List
Find contact information for Pulmotect. Learn about their Research & Development, Business Services market share, competitors, and Pulmotect's email format. See details»
Pulmotect - 2025 Company Profile & Team - Tracxn
Jun 20, 2025 Pulmotect is a series B company based in Houston (United States), founded in 2007 by Brenton Scott. It operates as a Developer of therapeutics against lung infections. … See details»
Pulmotect Company Profile - Office Locations, Competitors ... - Craft
Pulmotect has 5 employees at their 1 location and $11.9 m in total funding,. See insights on Pulmotect including office locations, competitors, revenue, financials, executives, subsidiaries … See details»
Pulmotect, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Jun 15, 2025 Explore Pulmotect, Inc. with its drug pipeline, therapeutic area, technology platform, 7 clinical trials, 5 news, and 5 literature, Disease Domain:Hemic and Lymphatic ... See details»
Pulmotect - Company info. interviews, news
PULMOTECT, INC. is a Houston-based clinical stage biotechnology company, developing products that boost the innate immune system to protect against a wide range of lung … See details»
Pulmotect, Inc. – Bio-pharmaceutical company developing …
Pulmotect’s lead product, PUL-042, is a clinical stage inhaled therapeutic that stimulates the innate immune system in the lungs to provide immediate and effective protection against viral, … See details»
Pulmotect 2025 Company Profile: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Pulmotect. Use the PitchBook Platform to explore the full profile. See details»
PULMOTECT, INC. Company Profile | Houston, TX - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for PULMOTECT, INC. of Houston, TX. Get the latest business insights from Dun & Bradstreet. See details»
PULMOTECT, INC - VentureRadar
Develops host-directed, pathogen-agnostic biopharmaceutical products to reduce morbidity and mortality in patients with severe respiratory diseases, offering broad-spectrum, fast-acting … See details»
Management Team – Pulmotect, Inc.
JOHN SCHAUMBERG, PhD Head, Clinical Development Dr. Schaumberg has more than 30 years of drug development expertise, including experience with global pharmaceutical … See details»
Pulmotect: Revenue, Worth, Valuation & Competitors 2025
About Pulmotect Pulmotect is a Biotech related company founded in 2007 and based in Houston with 9 employees an estimated revenue of $1.4M, and. It has 10 competitors including … See details»
Pulmotect - Funding, Financials, Valuation & Investors
Pulmotect is funded by 7 investors. Jefferson River Capital and Fannin Innovation Studio are the most recent investors. Which investors participated in the most funding rounds? See details»
Contact Us - Pulmotect, Inc.
Please click on one of the links below and we will respond back shortly: For general public, media, government, physician and other inquiries: General For investor inquiries: Investors For … See details»
Pulmotect - 2025 Funding Rounds & List of Investors - Tracxn
Jun 20, 2025 Pulmotect has raised a total funding of $25.1M over 13 rounds from 7 investors. Investors include NIH, HHS and 5 others. Their latest funding round was of $10.3M on Aug 30, … See details»
Telephus Medical CEO Mark Benedyk Joins Pulmotect, Inc
Jun 15, 2017 Pulmotect, Inc., a clinical-stage biotechnology company developing PUL-042, fast-acting pulmonary immune stimulant for the treatment of antibiotic-resistant respiratory … See details»
Pulmotect - Contacts, Employees, Board Members, Advisors
Pulmotect develops an inhaled therapeutic designed to prevent and treat respiratory infections. See details»
Our Pipeline – Pulmotect, Inc.
We are advancing our lead program, PUL-042, a first in class, patent protected, inhaled therapy that activates the innate immunity of the lungs for multiple indications. Our pipeline below … See details»
News – Pulmotect, Inc.
Jan 27, 2020 November 30, 2023 Pulmotect Awarded $8.9 Million from The State of Texas June 6, 2023 Pulmotect Provides Results from Two Randomized, Placebo Controlled Phase-2 … See details»